195 related articles for article (PubMed ID: 8525052)
1. CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy?
van Gool SW; Barcy S; Devos S; Vandenberghe P; Ceuppens JL; Thielemans K; de Boer M
Res Immunol; 1995; 146(3):183-96. PubMed ID: 8525052
[No Abstract] [Full Text] [Related]
2. The complexities of T-cell co-stimulation: CD28 and beyond.
Sperling AI; Bluestone JA
Immunol Rev; 1996 Oct; 153():155-82. PubMed ID: 9010723
[No Abstract] [Full Text] [Related]
3. Blocking CD40 - CD154 and CD80/CD86 - CD28 interactions during primary allogeneic stimulation results in T cell anergy and high IL-10 production.
Van Gool SW; Vermeiren J; Rafiq K; Lorr K; de Boer M; Ceuppens JL
Eur J Immunol; 1999 Aug; 29(8):2367-75. PubMed ID: 10458748
[TBL] [Abstract][Full Text] [Related]
4. Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86.
Lane P
Ann N Y Acad Sci; 1997 Apr; 815():392-400. PubMed ID: 9186685
[TBL] [Abstract][Full Text] [Related]
5. CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation.
Linsley PS; Ledbetter J; Peach R; Bajorath J
Res Immunol; 1995; 146(3):130-40. PubMed ID: 8525042
[No Abstract] [Full Text] [Related]
6. New protein steals the show as 'costimulator' of T cells.
Cohen J
Science; 1993 Nov; 262(5135):844-5. PubMed ID: 7694360
[No Abstract] [Full Text] [Related]
7. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
[TBL] [Abstract][Full Text] [Related]
8. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.
Linsley PS; Greene JL; Brady W; Bajorath J; Ledbetter JA; Peach R
Immunity; 1994 Dec; 1(9):793-801. PubMed ID: 7534620
[TBL] [Abstract][Full Text] [Related]
9. The role of CTLA-4 in the regulation and initiation of T-cell responses.
Chambers CA; Krummel MF; Boitel B; Hurwitz A; Sullivan TJ; Fournier S; Cassell D; Brunner M; Allison JP
Immunol Rev; 1996 Oct; 153():27-46. PubMed ID: 9010718
[No Abstract] [Full Text] [Related]
10. The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response.
Boussiotis VA; Freeman GJ; Gribben JG; Nadler LM
Immunol Rev; 1996 Oct; 153():5-26. PubMed ID: 9010717
[No Abstract] [Full Text] [Related]
11. B7-CD28 interaction is a late acting co-stimulatory signal for human T cell responses.
Zhang YQ; Joost van Neerven RJ; Van Gool SW; Coorevits L; de Boer M; Ceuppens JL
Int Immunol; 1997 Aug; 9(8):1095-102. PubMed ID: 9263006
[TBL] [Abstract][Full Text] [Related]
12. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions.
Greene JL; Leytze GM; Emswiler J; Peach R; Bajorath J; Cosand W; Linsley PS
J Biol Chem; 1996 Oct; 271(43):26762-71. PubMed ID: 8900156
[TBL] [Abstract][Full Text] [Related]
13. CTLA-4 and T cell activation.
Oosterwegel MA; Greenwald RJ; Mandelbrot DA; Lorsbach RB; Sharpe AH
Curr Opin Immunol; 1999 Jun; 11(3):294-300. PubMed ID: 10375557
[TBL] [Abstract][Full Text] [Related]
14. Cytokines and cancer immunotherapy.
Wolf SF; Lee K; Swiniarski H; O'Toole M; Sturmhoefel K
Immunol Invest; 2000 May; 29(2):143-6. PubMed ID: 10854183
[No Abstract] [Full Text] [Related]
15. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells.
Caux C; Vanbervliet B; Massacrier C; Azuma M; Okumura K; Lanier LL; Banchereau J
J Exp Med; 1994 Nov; 180(5):1841-7. PubMed ID: 7525840
[TBL] [Abstract][Full Text] [Related]
16. Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28.
Metzler WJ; Bajorath J; Fenderson W; Shaw SY; Constantine KL; Naemura J; Leytze G; Peach RJ; Lavoie TB; Mueller L; Linsley PS
Nat Struct Biol; 1997 Jul; 4(7):527-31. PubMed ID: 9228944
[TBL] [Abstract][Full Text] [Related]
17. CD28/CTLA-4 and CD80/CD86 costimulatory molecules are mainly involved in acceptance or rejection of human liver transplant.
Minguela A; Marín L; Torío A; Muro M; García-Alonso AM; Moya-Quiles MR; Sánchez-Bueno F; Parrilla P; Alvarez-López MR
Hum Immunol; 2000 Jul; 61(7):658-69. PubMed ID: 10880736
[TBL] [Abstract][Full Text] [Related]
18. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.
Freeman GJ; Gribben JG; Boussiotis VA; Ng JW; Restivo VA; Lombard LA; Gray GS; Nadler LM
Science; 1993 Nov; 262(5135):909-11. PubMed ID: 7694363
[TBL] [Abstract][Full Text] [Related]
19. Enhanced expression of CTLA-4 (CD152) on CD4+ T cells in HIV infection.
Steiner K; Waase I; Rau T; Dietrich M; Fleischer B; Bröker BM
Clin Exp Immunol; 1999 Mar; 115(3):451-7. PubMed ID: 10193417
[TBL] [Abstract][Full Text] [Related]
20. The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion.
Rennert P; Furlong K; Jellis C; Greenfield E; Freeman GJ; Ueda Y; Levine B; June CH; Gray GS
Int Immunol; 1997 Jun; 9(6):805-13. PubMed ID: 9199963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
